AMP German Cannabis Group Receives Import Licence for Medical Cannabis for Imports from European Union Countries


Ryan Allway

March 9th, 2020

News


BERLIN, March 9, 2020 /CNW/ – AMP German Cannabis Group Inc. (“AMP” or the “Company”) (CSE: XCX) (FSE: C4T, ISIN: CA00176G1028) announces that the Thuringian State Office for Consumer Protection or Thüringer Landesamt für Verbraucherschutz, (“TLV”) has granted an additional import licence for cannabis products for medical purposes from European countries to Germany in accordance to Paragraph §52a of the German Medicine Law or Arzneimittelgesetz to Alternative Medical Products GmbH (“AMP Germany”), a wholly-owned subsidiary of AMP.

TLV deals with fundamental matters of economic consumer protection and consumer policy for the Free State of Thuringia in Germany and grants the necessary licenses and permits for the import of medical cannabis into Germany to AMP.

With both the §52a and §72 licences from TLV, AMP can import and wholesale medical cannabis into the German pharmaceutical market with EU-GMP cannabis purchased from within and outside the European Union.

In addition, AMP anticipates receiving an irradiation permit to cover all possible medical cannabis production methods and completing the EU-GMP audit of its supply chain to guarantee a well-functioning supply chain to pharmacies and patients. Currently, all medical cannabis distributed in Germany is irradiated. The completion of the EU-GMP supply chain audit and irradiation permit are required to import from the Netherlands.

Dr. Stefan Feuerstein, Managing Director of AMP Germany, commented: “Being granted an additional licence for European Union imports [§52a AMG of the German Medicine Law] will allow AMP to begin importing from the Netherlands in early Q2 of 2020.  Moreover, we expect our irradiation permit shortly, which is important in regard to our planned imports from the Netherlands and from Canada during Q3 of 2020.”

About AMP German Cannabis Group Inc.

AMP German Cannabis Group is a specialized importer of EU-GMP medical cannabis into Germany.  For more information, please visit: www.amp-eu.com.

AMP social media links: Twitter, LinkedIn, and Facebook. Media Kit:  www.amp-eu.com/media-kit

SOURCE AMP German Cannabis Group Inc.

For further information: Mr. Alex Blodgett, CEO and Director, Telephone: +236-833-1602, Canada: investor@amp-eu.com, Germany: investor@amp-eu.de

Related Links

http://www.amp-eu.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading